Enzo Biochem, Inc. (ENZ) Stock Analysis

Enzo Biochem, Inc. (ENZ) Healthcare & Pipeline Overview

Enzo Biochem, Inc. is a healthcare company specializing in integrated diagnostics, clinical lab services, and life sciences. The company develops and markets diagnostic and research products based on genetic engineering, serving clinical research, drug development, and bioscience research customers, positioning itself within the broader medical diagnostics market.

What Is the Investment Thesis for ENZ?

Enzo Biochem, Inc. presents a multifaceted investment case centered on its integrated approach to diagnostics, clinical lab services, and therapeutics. With a market capitalization of $16.4M, the company's growth potential is tied to its ability to innovate and expand its product offerings within the life sciences sector. Key value drivers include the expansion of the Clinical Laboratory Services segment, particularly through its network of patient service centers and rapid response laboratories. The company's gross margin of 45.6% indicates a solid foundation for profitability, though its negative profit margin of -31.5% highlights the need for improved cost management and revenue generation. Upcoming catalysts include potential advancements in its therapeutics pipeline and expansion of its diagnostic product lines. However, investors should be aware of potential risks such as competition, regulatory changes, and the need for additional funding to support ongoing research and development.

Based on FMP financials and quantitative analysis

ENZ Key Highlights

Market Cap of $16.4M reflects its position as a smaller player in the diagnostics and research market.

• Gross Margin of 45.6% indicates solid pricing power and efficient cost management in its product offerings.
• Profit Margin of -31.5% highlights challenges in achieving profitability, requiring focus on cost reduction and revenue growth.
• Beta of 1.16 suggests that the stock is slightly more volatile than the market, potentially offering higher returns but also greater risk.
• Operates three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics, diversifying its revenue streams and market reach.

Who Are ENZ's Competitors?

ENZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ENZ's Key Strengths?

Integrated business model.

• Proprietary technologies.
• Established clinical laboratory network.
• Diverse product and service offerings.

What Are ENZ's Weaknesses?

Negative profit margin.

• Smaller market capitalization compared to competitors.
• Reliance on research and development for future growth.
• Potential competition from larger, more established players.

What Could Drive ENZ Stock Higher?

Potential advancements in the therapeutics pipeline.

• Expansion of diagnostic product lines.
• Strategic partnerships and collaborations to expand market reach.
• Innovation in diagnostic technologies to improve testing services.

What Are the Key Risks for ENZ?

Financial-distress signal — its Altman Z-Score of -5.57 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-9.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from larger diagnostic and research companies.
• Regulatory changes and compliance requirements impacting operations.
• Technological advancements rendering existing products obsolete.
• Need for additional funding to support research and development.
• Economic downturn affecting healthcare spending and demand for services.

What Are the Growth Opportunities for ENZ?

• Expansion of Clinical Laboratory Services: Enzo Biochem can expand its Clinical Laboratory Services segment by increasing the number of patient service centers and rapid response laboratories in key markets. This expansion can drive revenue growth by providing convenient and accessible testing services to a broader patient base. The market for clinical laboratory services is projected to grow, driven by increasing demand for diagnostic testing and personalized medicine. Timeline: Ongoing.
• Development of Novel Therapeutics: The Therapeutics segment offers significant growth potential through the development of novel approaches in areas such as gastrointestinal, infectious, ophthalmic, and metabolic diseases. Successful development and commercialization of new therapeutics can generate substantial revenue streams and enhance the company's market position. The market for therapeutics is vast, with opportunities to address unmet medical needs and improve patient outcomes. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: Enzo Biochem can pursue strategic partnerships and collaborations with other companies in the healthcare industry to expand its product offerings, access new markets, and leverage complementary expertise. These partnerships can accelerate product development, reduce costs, and enhance the company's competitive position. The market for healthcare partnerships is active, with opportunities to collaborate on research, development, and commercialization efforts. Timeline: Ongoing.
• Geographic Expansion: Enzo Biochem can expand its geographic reach by entering new markets and establishing a presence in regions with high growth potential. This expansion can drive revenue growth by tapping into new customer bases and diversifying its revenue streams. The global market for diagnostics and research products is expanding, with opportunities to capitalize on emerging markets. Timeline: Ongoing.
• Innovation in Diagnostic Technologies: Enzo Biochem can invest in research and development to innovate new diagnostic technologies and improve the accuracy, speed, and cost-effectiveness of its testing services. This innovation can attract new customers, differentiate the company from competitors, and drive revenue growth. The market for diagnostic technologies is constantly evolving, with opportunities to develop and commercialize innovative solutions. Timeline: Ongoing.

What Are ENZ's Competitive Advantages?

• Integrated business model combining diagnostics, clinical lab services, and therapeutics.
• Proprietary technologies and intellectual property in genetic engineering and molecular biology.
• Established network of patient service centers and rapid response laboratories.
• Direct sales force and distributor network providing market access.

What Does ENZ Do?

Founded in 1976 and headquartered in New York City, Enzo Biochem, Inc. operates as an integrated diagnostics, clinical lab, and life sciences company. The company researches, develops, manufactures, and markets a range of diagnostic and research products leveraging genetic engineering, biotechnology, and molecular biology. Enzo Biochem operates through three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment focuses on developing, manufacturing, and marketing products and tools for clinical research, drug development, and bioscience research, offering proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests used in patient care, operating a full-service clinical laboratory in Farmingdale, New York, along with a network of patient service centers and rapid response laboratories. The Therapeutics segment focuses on developing novel approaches in areas such as gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem markets its products and services through a direct sales force and a network of distributors both in the United States and internationally.

What Products and Services Does ENZ Offer?

• Researches, develops, manufactures, and markets diagnostic and research products.
• Offers products based on genetic engineering, biotechnology, and molecular biology.
• Provides clinical laboratory services, including molecular and other clinical tests.
• Operates a network of patient service centers and rapid response laboratories.
• Develops novel therapeutic approaches in areas such as gastrointestinal and infectious diseases.
• Markets products and services through a direct sales force and distributor network.

How Does ENZ Make Money?

• Generates revenue from the sale of life sciences products to research and development customers.
• Earns revenue from clinical laboratory services provided to physicians and patients.
• Seeks to generate revenue from the development and commercialization of therapeutic products.
• Utilizes a direct sales force and distributor network to market its products and services.

What Industry Does ENZ Operate In?

Enzo Biochem, Inc. operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and growing awareness of early disease detection. Enzo Biochem competes with larger, more established players in the diagnostics market, as well as specialized research and development firms. The company's integrated approach, combining diagnostics, clinical lab services, and therapeutics, differentiates it from some competitors. However, it faces challenges in scaling its operations and competing on price with larger companies.

Who Are ENZ's Key Customers?

• Clinical research institutions and drug development companies.
• Physicians and healthcare providers.
• Patients seeking diagnostic testing services.
• Bioscience research customers.

How Enzo Biochem, Inc. Is Valued

Enzo Biochem, Inc. carries a market capitalization of $16.4M, placing it in the micro-cap category.

Company Profile

Enzo Biochem, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Kara Cannon. ENZ has traded publicly since 1980.

Return on equity for Enzo Biochem, Inc. stands at -9.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.84 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.8%, the inverse of the P/E and a quick read on earnings relative to price.

Enzo Biochem, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.57 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Enzo Biochem, Inc. revenue of about $107.0M for fiscal 2026, with EPS near $-0.07.

ENZ Financials

ENZ Latest News

Enzo Biochem, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources